Danaher Corporation Finalizes Acquisition of Masimo Corporation for Advanced Patient Monitoring

Danaher Completes Acquisition of Masimo Corporation

On June 10, 2026, Danaher Corporation, a renowned leader in science and technology, officially announced that it has completed its acquisition of Masimo Corporation. This strategic move enhances Danaher’s diagnostic capabilities in the critical field of patient monitoring solutions, particularly for acute care settings. Masimo is widely recognized for its innovative pulse oximetry technology and other diagnostic tools that are critical in healthcare environments, making this acquisition a significant milestone for Danaher.

The Merger's Significance

With Masimo now a wholly-owned subsidiary of Danaher, it will continue to operate independently under its established brand name, retaining its identity while benefiting from Danaher’s global reach and resources. The integration into Danaher’s Diagnostics segment allows for the synergistic merging of technologies and capabilities that both companies bring to the table.

Julie Sawyer Montgomery, Danaher’s Executive Vice President of Diagnostics, expressed her enthusiasm about the acquisition. She stated, “Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo's growth and global reach.” Montgomery's vision indicates a commitment to enhancing the effectiveness and reach of medical technology to benefit patient care globally.

Financial Implications

As per the merger agreement, the financial terms and conditions for former Masimo stockholders will be executed as outlined in the definitive transaction materials that were filed with the U.S. Securities and Exchange Commission. Danaher has clarified that there will be no changes to its previously communicated financial guidance for the second quarter and full year of 2026, excluding the anticipated contributions from Masimo. Expectations suggest that Masimo is not expected to make a material contribution to Danaher’s financial performance in the second quarter of 2026, with further adjustments being considered for the full year following the integration process.

About Danaher and Masimo

Danaher Corporation is dedicated to leveraging advanced science and technology to drive improvements in human health. With approximately 60,000 associates worldwide, the company is committed to solving complex scientific and clinical challenges, ensuring innovations progress from the laboratory to the market effectively.

Masimo Corporation, on the other hand, has positioned itself as a pioneer in the realm of patient monitoring solutions. The company’s products harness advanced technology to deliver reliable data that healthcare providers depend on for critical decision-making in emergencies. For both organizations, this merger signals a new chapter of innovation and commitment to transforming healthcare practices by enhancing medical diagnostics.

Looking Ahead

As healthcare challenges continue to evolve, the merger between Danaher and Masimo represents a holistic approach to advancing patient care technologies. Both companies are poised to drive forward-thinking solutions that improve health outcomes worldwide, waiting to be embraced by a rapidly growing global healthcare market. The selected integration strategies and continuous improvement processes promise to redefine patient monitoring and diagnostics, showcasing the potential benefits of such a powerful collaboration.

This acquisition sets a precedent in the healthcare sector, emphasizing the importance of innovation, strategic alliances, and strengthening capabilities that lead to improved patient outcomes and enhanced operational efficiency. The future looks promising as Danaher and Masimo join forces in a mission to provide exceptional care that ultimately benefits patients around the globe.